Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Patients with and without obesity experienced significant pain reductions and improved functioning following telerehabilitation for chronic musculoskeletal pain.

The following is a summary of “Real-world satisfaction and experience with injection and autoinjector device for ofatumumab ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

On Amazon, a good product rating percentage is generally considered to be 80% or higher, which corresponds to a four-star ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

We view Fanuc’s capital allocation as Exemplary, as the company has been efficiently allocating capital to both its operations and shareholders. Fanuc’s balance sheet has been healthy, without any ...

Results of a study showed administration of IV tranexamic acid within 15 minutes of incision did not significantly improve ...

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...